Urology will make a modest gain overall in the 2020 final rule for the Medicare Physician Fee Schedule, although the truly significant changes won’t be felt until 2021.
In this interview, Chandru P. Sundaram, MD, explains the important patient and tumor characteristics to consider in deciding between partial and radical nephrectomy.
November 2019 proved to be a fruitful month for urology-specific FDA approvals, with the agency giving the green light to a new drug for complicated urinary tract infection, an implantable device for the treatment of overactive bladder/retention, and a digital product for strengthening of pelvic floor muscles and treatment of urinary incontinence in women.
It may be time to take a closer look at antibiotic prophylaxis prior to ureteral stent removal, according to new data reported at the AUA annual meeting in Chicago.
Guideline-directed care often leads to better outcomes, but that’s not the case with the AUA’s antibiotic prophylaxis guidelines for diabetic patients undergoing primary penile prosthesis implantation. Authors of an ongoing study have found that adhering to the antibiotic prophylaxis guidelines results in a five-fold increased infection risk among diabetic penile prothesis patients, greatly increasing their risk for explantation.
A study investigating discharge destination and perioperative complications after radical cystectomy provides useful data for risk stratification and preoperative counseling of patients 80 years of age and older, said Hayden M. Hill, MD, who presented the research at the American College of Surgeons Clinical Congress in San Francisco.
Newly diagnosed low- and high-risk prostate cancer patients seen during the same appointment by a urologist and radiation oncologist were more likely than patients in a nationwide cohort to choose evidence-based care, according to a recent study.
“There is now sufficient data to support the use of prostate MRI in all men before their initial prostate biopsy when the MRI is of sufficient quality,” says policy statement co-author Marc A. Bjurlin, DO, MSc.
Results from analyses of data collected in the randomized, placebo-controlled Reduction by Dutasteride of prostate Cancer Events (REDUCE) trial point to a potential role for statins in attenuating age-related prostate enlargement.